Actinium Pharmaceuticals (NYSE:ATNM) Shares Up 1.9% – What’s Next?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM)’s share price was up 1.9% during trading on Tuesday . The stock traded as high as $0.9201 and last traded at $0.90. Approximately 50,584 shares changed hands during trading, a decline of 65% from the average daily volume of 145,028 shares. The stock had previously closed at $0.8830.

Wall Street Analysts Forecast Growth

Separately, Stephens restated an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $5.00.

Actinium Pharmaceuticals Stock Performance

The stock has a market capitalization of $28.24 million, a P/E ratio of -0.65 and a beta of -0.02. The business has a 50 day simple moving average of $1.05 and a 200-day simple moving average of $1.15.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in Actinium Pharmaceuticals during the second quarter worth about $306,000. Two Sigma Investments LP raised its position in Actinium Pharmaceuticals by 403.4% in the third quarter. Two Sigma Investments LP now owns 234,293 shares of the company’s stock worth $375,000 after acquiring an additional 187,748 shares in the last quarter. Renaissance Technologies LLC raised its position in Actinium Pharmaceuticals by 35.4% in the fourth quarter. Renaissance Technologies LLC now owns 390,784 shares of the company’s stock worth $531,000 after acquiring an additional 102,154 shares in the last quarter. Marshall Wace LLP acquired a new stake in Actinium Pharmaceuticals in the 2nd quarter valued at about $137,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Actinium Pharmaceuticals in the 4th quarter valued at about $96,000. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.